Mercer Global Advisors
REGN icon

Mercer Global Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Mercer Global Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.5M Buy
20,053
+4,917
+32% +$3.76M 0.02% 380
2025
Q4 		$11.7M Buy
15,136
+2,796
+23% +$1.9M 0.02% 453
2025
Q3 		$6.94M Buy
12,340
+6,630
+116% +$3.75M 0.01% 561
2025
Q2 		$3M Sell
5,710
-2,720
-32% -$1.52M 0.01% 734
2025
Q1 		$5.35M Sell
8,430
-14,954
-64% -$10.3M 0.01% 522
2024
Q4 		$16.7M Sell
23,384
-2,389
-9% -$2M 0.04% 250
2024
Q3 		$27M Buy
25,773
+1,454
+6% +$1.62M 0.06% 162
2024
Q2 		$25.5M Buy
24,319
+1,122
+5% +$1.09M 0.07% 164
2024
Q1 		$22.3M Buy
23,197
+1,328
+6% +$1.26M 0.06% 183
2023
Q4 		$19.2M Buy
21,869
+869
+4% +$716K 0.06% 201
2023
Q3 		$17.3M Buy
21,000
+1,713
+9% +$1.35M 0.07% 187
2023
Q2 		$13.9M Buy
19,287
+883
+5% +$681K 0.06% 226
2023
Q1 		$15.1M Sell
18,404
-489
-3% -$369K 0.07% 203
2022
Q4 		$13.6M Buy
18,893
+1,218
+7% +$899K 0.07% 210
2022
Q3 		$12.2M Buy
17,675
+1,480
+9% +$931K 0.07% 201
2022
Q2 		$9.57M Buy
16,195
+2,806
+21% +$1.82M 0.06% 233
2022
Q1 		$9.35M Buy
13,389
+5,423
+68% +$3.43M 0.06% 238
2021
Q4 		$5.03M Buy
7,966
+4,264
+115% +$2.62M 0.03% 370
2021
Q3 		$2.24M Buy
3,702
+87
+2% +$54K 0.02% 570
2021
Q2 		$2.02M Sell
3,615
-2,447
-40% -$1.24M 0.02% 566
2021
Q1 		$2.87M Buy
6,062
+1,710
+39% +$833K 0.03% 426
2020
Q4 		$2.1M Buy
4,352
+1,788
+70% +$965K 0.03% 410
2020
Q3 		$1.44M Buy
2,564
+1,758
+218% +$1.07M 0.02% 464
2020
Q2 		$503K Buy
806
+6
+0.8% +$3.41K 0.01% 681
2020
Q1 		$391K Buy
800
+84
+12% +$34.6K 0.01% 737
2019
Q4 		$269K Buy
+716
New +$241K 0.01% 958

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Mercer Global Advisors's REGN Position: Q1 2026 in Review

Mercer Global Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 32% in Q1 2026, buying an estimated $3.76M and bringing the position to 20,053 shares worth $15.5M. The position accounts for 0.02% of the portfolio, ranked #380.

Mercer Global Advisors first reported a position in REGN in Q4 2019 and has held it in 26 quarters since. The position peaked at $27M in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Mercer Global Advisors held 20,053 shares of Regeneron Pharmaceuticals worth $15.5M as of Q1 2026.
  • Mercer Global Advisors bought 4,917 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $3.76M.
  • Regeneron Pharmaceuticals made up 0.02% of Mercer Global Advisors's portfolio in Q1 2026, its #380 holding.
  • Mercer Global Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2019 and has held it in 26 quarters since.
  • Mercer Global Advisors's Regeneron Pharmaceuticals position peaked at $27M in Q3 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.